<?xml version="1.0" encoding="UTF-8"?>
<p>Safety endpoints will be assessed throughout the 24‐week dose‐evaluation phase and will include the incidence of all AEs; short‐term tolerance parameters, including vital signs; physical and neurological examination findings; and laboratory parameters (haematology and clinical chemistry) and tests for viral safety.</p>
